Merck's Winrevair Approved For Pulmonary Arterial Hypertension In Canada
5/9 02:59
(RTTNews) - Merck (MRK) announced that Winrevair or sotatercept is now authorized for use in Canada in combination with standard pulmonary arterial hypertension or PAH therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class II or...